The WoVen Podcast
Canaan on Twitter
Canaan on LinkedIn
© Copyright 2022 Canaan |
Latest for Vivace Therapeutics
A milestone in targeted oncology and looking ahead
In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.
Endpoints News: Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year
With $30 million in Series C financing, Vivace is aiming to test one of its candidates against that pathway starting in early 2021.
Fierce Biotech: Vivace snares $30M to push Hippo-targeting drugs into the clinic
Fierce Biotech: Vivace uncloaks with $40M, U.S./China backing for cancer trials
Tim Shannon: Durable bonds and the birth of Vivace Therapeutics